USANC OKs pimavanserin tartrate as new name for ACP-103
San Diego, USA-based biopharmaceutical firm Acadia Pharmaceuticals says that the US Adopted Names Council (USANC) has approved the non-proprietary name "pimavanserin tartrate" for its developmental drug candidate, ACP-103.
The drug, which recently achieved positive results in a Phase II trial (Marketletter March 26), is a selective 5-HT2A inverse agonist that is being developed for use in a range of indications, including: schizophrenia, Parkinson's disease and sleep maintenance in insomnia. Acadia also said that it is planning to initiate the first of two Phase III trials of the compound in Parkinson's disease, specifically as a treatment for the psychosis associated with the condition, in the next few months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze